Sergio Padilla

Valencia, VC, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 79 publications

Correction: Longitudinal changes in circulating biomarkers from baseline to week 48 in treatment-Naïve people living with HIV initiating integrase inhibitor-based antiretroviral therapy.

Correction: Longitudinal changes in circulating biomarkers from baseline to week 48 in treatment-Naïve people living with HIV initiating integrase inhibitor-based antiretroviral therapy.

Journal: PloS one

Published: July 24, 2026

Working-memory effects of prefrontal tDCS across baseline cognitive-severity groups in schizophrenia: A secondary analysis of a randomized double-blind sham-controlled trial.

Working-memory effects of prefrontal tDCS across baseline cognitive-severity groups in schizophrenia: A secondary analysis of a randomized double-blind sham-controlled trial.

Journal: Schizophrenia research. Cognition

Published: June 16, 2026

Low prevalence of bacterial coinfection at hospital admission in COVID-19 and the role of procalcitonin as a rule-out biomarker (Revised Version).

Low prevalence of bacterial coinfection at hospital admission in COVID-19 and the role of procalcitonin as a rule-out biomarker (Revised Version).

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: April 02, 2026

Antiviral therapy and interleukin-6 blockade associated with lower thrombotic risk in hospitalized COVID-19: a target trial emulation.

Antiviral therapy and interleukin-6 blockade associated with lower thrombotic risk in hospitalized COVID-19: a target trial emulation.

Journal: Scientific reports

Published: March 28, 2026

Contribution of hepatic steatosis to subclinical atherosclerosis progression in people with HIV receiving integrase inhibitors: a 5-year prospective cohort study.

Contribution of hepatic steatosis to subclinical atherosclerosis progression in people with HIV receiving integrase inhibitors: a 5-year prospective cohort study.

Journal: AIDS (London, England)

Published: January 03, 2026

Impact of Gluteal Injection Site on Pharmacokinetics and Tolerability of Antiretroviral Therapy with Long-Acting Cabotegravir and Rilpivirine.

Impact of Gluteal Injection Site on Pharmacokinetics and Tolerability of Antiretroviral Therapy with Long-Acting Cabotegravir and Rilpivirine.

Journal: AIDS patient care and STDs

Published: November 17, 2025

Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort.

Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort.

Journal: Journal of the International AIDS Society

Published: October 11, 2025

Point-of-care ultrasound guidance for long-acting cabotegravir-rilpivirine administration improves injection-site tolerability and preserves pharmacokinetics.

Point-of-care ultrasound guidance for long-acting cabotegravir-rilpivirine administration improves injection-site tolerability and preserves pharmacokinetics.

Journal: AIDS (London, England)

Published: September 14, 2025

Virological Success With Long-Acting Cabotegravir and Rilpivirine Despite Historical Rilpivirine Resistance: A Real-World Case Series.

Virological Success With Long-Acting Cabotegravir and Rilpivirine Despite Historical Rilpivirine Resistance: A Real-World Case Series.

Journal: Open forum infectious diseases

Published: July 28, 2025

Clinical outcomes of long-acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real-world data from the Spanish RELATIVITY cohort.

Clinical outcomes of long-acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real-world data from the Spanish RELATIVITY cohort.

Journal: HIV medicine

Published: July 28, 2025

Longitudinal changes in circulating biomarkers from baseline to week 48 in treatment-Naïve people living with HIV initiating integrase inhibitor-based antiretroviral therapy.

Longitudinal changes in circulating biomarkers from baseline to week 48 in treatment-Naïve people living with HIV initiating integrase inhibitor-based antiretroviral therapy.

Journal: PloS one

Published: July 11, 2025

Longitudinal changes in circulating biomarkers from baseline to week 48 in treatment-Naïve people living with HIV initiating integrase inhibitor-based antiretroviral therapy.

Longitudinal changes in circulating biomarkers from baseline to week 48 in treatment-Naïve people living with HIV initiating integrase inhibitor-based antiretroviral therapy.

Journal: PloS one

Published: July 11, 2025

Showing 1-12 of 79

Last Updated: 09/26/2026